Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the CXCL3 function in HTR-8/Svneo was analyzed via WST-1 assay, flow cytometry and invasion test.
|
25485631 |
2014 |
Leishmaniasis, Cutaneous
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increased expression levels of cxcl5 (P < 0.05), ccl8, and cxcl3 were corroborated in chronic CL lesions.
|
24752514 |
2014 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 and its receptor CXCR2 were considered to play particularly important roles in the progression of malignancies.
|
26837773 |
2016 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, high-level CXCL3 can be secreted by PC-3 and RWPE-1, and CXCL3 protein expression level in tissue microarray is concordant with prostate cancer metastasis.
|
26837773 |
2016 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, high-level CXCL3 can be secreted by PC-3 and RWPE-1, and CXCL3 protein expression level in tissue microarray is concordant with prostate cancer metastasis.
|
26837773 |
2016 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We further examined whether CXCL3 could regulate the expression of genes correlated with prostate tumorigenesis by RT- PCR.
|
26837773 |
2016 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, high-level CXCL3 can be secreted by PC-3 and RWPE-1, and CXCL3 protein expression level in tissue microarray is concordant with prostate cancer metastasis.
|
26837773 |
2016 |
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
TNF-induced mRNA stabilization in RA FLS occurs during the late phase of TNF response, is MAPK-dependent, and involves several genes with pathogenic potential such as IL6, CXCL1, CXCL3, CXCL8/IL8, CCL2, and PTGS2.
|
28708839 |
2017 |
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Comparing inflammatory cytokine response to S. aureus BSI in HD patients to non-HD patients, IL-6 and GROγ were significantly lower (p = 0.021 and p = 0.001, respectively) in HD patients compared to other patients on the day of diagnosis and RANTES levels were significantly lower (p = 0.025) in HD patients on day 7 following diagnosis.
|
27638007 |
2017 |
Huntington Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Comparing inflammatory cytokine response to S. aureus BSI in HD patients to non-HD patients, IL-6 and GROγ were significantly lower (p = 0.021 and p = 0.001, respectively) in HD patients compared to other patients on the day of diagnosis and RANTES levels were significantly lower (p = 0.025) in HD patients on day 7 following diagnosis.
|
27638007 |
2017 |
Subarachnoid Hemorrhage
|
0.010 |
Biomarker
|
disease |
BEFREE |
Real-time PCR data demonstrated that baicalin attenuated increased proinflammatory cytokine (IL-1<i>β</i>, IL-6, and CXCL-3) production in subarachnoid hemorrhage mice.
|
28912935 |
2017 |
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
IL-17 stimulated ESCC tumor cells to release more of the CXC chemokines CXCL2 and CXCL3, which are involved in neutrophil migration.
|
29296528 |
2017 |
Heart Failure, Diastolic
|
0.300 |
Biomarker
|
disease |
CTD_human |
In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.
|
29556499 |
2018 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Molecular and functional characterization of tumor-induced factor (TIF): Hamster homolog of CXCL3 (GRO<sub>γ</sub>) displays tumor suppressive activity.
|
29276973 |
2018 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
CCK-8, transwell assays and growth of tumor xenografts were conducted to characterize the effects of CXCL3 on PC-3 cells' proliferation and migration.
|
29524043 |
2018 |
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that CXCL3 autocrine/paracrine pathways are involved in the development of prostate cancer by regulating the expression of the target genes that are related to the progression of malignancies.
|
29524043 |
2018 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 was reportedly associated with the invasion and metastasis of various malignancies, the role of CXCL3, however, in preeclampsia has not been fully discussed.
|
29884302 |
2018 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CXCL3 was reportedly associated with the invasion and metastasis of various malignancies, the role of CXCL3, however, in preeclampsia has not been fully discussed.
|
29884302 |
2018 |
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that CXCL3 autocrine/paracrine pathways are involved in the development of prostate cancer by regulating the expression of the target genes that are related to the progression of malignancies.
|
29524043 |
2018 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Western blotting was conducted to test whether CXCL3 could affect the expression of tumorigenesis-associated genes.
|
29524043 |
2018 |
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that CXCL3 autocrine/paracrine pathways are involved in the development of prostate cancer by regulating the expression of the target genes that are related to the progression of malignancies.
|
29524043 |
2018 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The result suggests that CXCL3 is involved in migration, invasion, proliferation and tubule formation of trophoblasts and may play a key role in the pathogenesis of preeclampsia.
|
29884302 |
2018 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
KRAS<sup>∗</sup>-mediated repression of IRF2 results in high expression of CXCL3, which binds to CXCR2 on myeloid-derived suppressor cells and promotes their migration to the tumor microenvironment.
|
30905761 |
2019 |